Yan Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yan Jiang has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Jisheng Zhang
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China
3 shared publicationsTing Chen
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China
3 shared publicationsXin Cui
Qingdao Women and Children’s Hospital, Qingdao University, Qingdao, China
3 shared publicationsYanfang Niu
Department of Clinical Laboratory, Yuncheng Central Hospital, Yuncheng, China
3 shared publicationsYichuan Huang
Deparment of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
3 shared publicationsZhiyuan Li
Department of Otolaryngology-Head and Neck Surgery, Key Laboratory, Affiliated Hospital of Qingdao University, No. 1677 Wutaishan Road, Qingdao, 266000, China
3 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 713
Neuroscience-guided bilateral thalamic MRI deep learning for obstructive sleep apnea diagnosis: a dual-center translational study
Obstructive sleep apnea (OSA) remains substantially underdiagnosed, and recurrent intermittent hypoxia (IH) is a key pathophysiological feature of OSA and
- 31 July 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 713
Open AccessNeuroscience-guided bilateral thalamic MRI deep learning for obstructive sleep apnea diagnosis: a dual-center translational study
Obstructive sleep apnea (OSA) remains substantially underdiagnosed, and recurrent intermittent hypoxia (IH) is a key pathophysiological feature of OSA and
- 1 January 2024
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 14 (6) , 3142-3152
The use of adjuvant chemotherapy combined with concurrent chemoradiotherapy enhances survival rates in cases of locally advanced nasopharyngeal carcinoma
This study aimed to evaluate the impact of adjuvant chemotherapy on survival rates, adverse events, and quality of life (QOL) in patients with locally advanced nasopharyngeal carcinoma (NPC). A retrospective cohort study was conducted, including patients with firstly histologically confirmed non-metastatic stage III-IVB NPC between February 2018 and February 2020, and with continuous follow-up data available, were chosen from the medical records of the affiliated hospital of Qingdao University and Zibo Central Hospital. There were 395 patients receiving concurrent chemoradiotherapy (CCRT) with adjuvant chemotherapy (adjuvant chemotherapy group) and 428 patients receiving CCRT alone (control group). The two groups were compared for treatment response, adverse events, and QOL scores. Besides, Kaplan-Meier plots, and multivariate COX analysis were conducted. The adjuvant chemotherapy group demonstrated a significantly higher overall survival and disease-free survival compared to the control group. The use of adjuvant chemotherapy was significantly correlated with improved overall survival and disease-free survival. Adjuvant chemotherapy was associated with reduced local recurrence and distant metastasis rates. However, higher rates of adverse events were observed in the adjuvant chemotherapy group. QOL scores for physical functioning, emotional functioning, and overall quality of life were higher in the adjuvant chemotherapy group. The findings of this study indicate that adjuvant chemotherapy in locally advanced NPC is associated with improved treatment response, extended overall and disease-free survivals, and better QOL, despite higher rates of adverse events.
- 1 January 2024
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 14 (6) , 3142-3152
The use of adjuvant chemotherapy combined with concurrent chemoradiotherapy enhances survival rates in cases of locally advanced nasopharyngeal carcinoma
This study aimed to evaluate the impact of adjuvant chemotherapy on survival rates, adverse events, and quality of life (QOL) in patients with locally advanced nasopharyngeal carcinoma (NPC). A retrospective cohort study was conducted, including patients with firstly histologically confirmed non-metastatic stage III-IVB NPC between February 2018 and February 2020, and with continuous follow-up data available, were chosen from the medical records of the affiliated hospital of Qingdao University and Zibo Central Hospital. There were 395 patients receiving concurrent chemoradiotherapy (CCRT) with adjuvant chemotherapy (adjuvant chemotherapy group) and 428 patients receiving CCRT alone (control group). The two groups were compared for treatment response, adverse events, and QOL scores. Besides, Kaplan-Meier plots, and multivariate COX analysis were conducted. The adjuvant chemotherapy group demonstrated a significantly higher overall survival and disease-free survival compared to the control group. The use of adjuvant chemotherapy was significantly correlated with improved overall survival and disease-free survival. Adjuvant chemotherapy was associated with reduced local recurrence and distant metastasis rates. However, higher rates of adverse events were observed in the adjuvant chemotherapy group. QOL scores for physical functioning, emotional functioning, and overall quality of life were higher in the adjuvant chemotherapy group. The findings of this study indicate that adjuvant chemotherapy in locally advanced NPC is associated with improved treatment response, extended overall and disease-free survivals, and better QOL, despite higher rates of adverse events.
- Open Access
- 13 March 2023
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 21 (1) , 1-18
Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis
Background: The aberrant expression of BRIP1 was associated with several cancers; however, the panoramic picture of BRIP1 in human tumors remains unclear. This study aims to explore the pan-cancerous picture of the expression of BRIP1 across 33 human cancers. Methods: Based on the data from TCGA and GTEx, a series of bioinformatic analyses were applied to systematically explore the genetic landscape and biologic function of BRIP1 in 33 human tumors. Results: We observed prognosis-related differential BRIP1 expressions between various carcinomas and the corresponding normal tissues. “Basal transcription factors,” “homologous recombination,” “nucleotide excision repair,” and DNA metabolism pathways may play a role in the functional mechanisms of BRIP1. Patients with uterine corpus endometrial carcinoma presented with the highest alteration frequency of BRIP1 (nearly 10%). Single-nucleotide and copy number variations of BRIP1 were noticed in multiple cancers, and the expression of BRIP1 is significantly regulated by copy number variation in breast invasive carcinoma and lung squamous cell carcinoma. BRIP1 expression is negatively correlated with the DNA methylation levels in many tumors and is associated with the activation of apoptosis, cell cycle, DNA damage response, and inhibition of hormone ER and RNS/MARK signaling pathways. Moreover, a positive correlation was observed between BRIP1 expression and the immune infiltration levels of cancer-associated fibroblasts and CD8+ T cells in lung adenocarcinoma. Conclusion: Our pan-cancer analysis of BRIP1 provides a valuable resource for understanding the multimolecular characteristics and biological function of BRIP1 across human cancers.
- 13 March 2023
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 21 (1) , 1-18
Open AccessMultimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis
Background: The aberrant expression of BRIP1 was associated with several cancers; however, the panoramic picture of BRIP1 in human tumors remains unclear. This study aims to explore the pan-cancerous picture of the expression of BRIP1 across 33 human cancers. Methods: Based on the data from TCGA and GTEx, a series of bioinformatic analyses were applied to systematically explore the genetic landscape and biologic function of BRIP1 in 33 human tumors. Results: We observed prognosis-related differential BRIP1 expressions between various carcinomas and the corresponding normal tissues. “Basal transcription factors,” “homologous recombination,” “nucleotide excision repair,” and DNA metabolism pathways may play a role in the functional mechanisms of BRIP1. Patients with uterine corpus endometrial carcinoma presented with the highest alteration frequency of BRIP1 (nearly 10%). Single-nucleotide and copy number variations of BRIP1 were noticed in multiple cancers, and the expression of BRIP1 is significantly regulated by copy number variation in breast invasive carcinoma and lung squamous cell carcinoma. BRIP1 expression is negatively correlated with the DNA methylation levels in many tumors and is associated with the activation of apoptosis, cell cycle, DNA damage response, and inhibition of hormone ER and RNS/MARK signaling pathways. Moreover, a positive correlation was observed between BRIP1 expression and the immune infiltration levels of cancer-associated fibroblasts and CD8+ T cells in lung adenocarcinoma. Conclusion: Our pan-cancer analysis of BRIP1 provides a valuable resource for understanding the multimolecular characteristics and biological function of BRIP1 across human cancers.
- Open Access
- 23 March 2022
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 79, 10200
Case Report: Recessive Dystrophic Epidermolysis Bullosa With Severe Esophageal Stenosis: A Case Report and Literature Review
Epidermolysis bullosa (EB) is a rare genetic disease that has no effective management or cure. Patients with EB may manifest with skin and mucous membrane fragility, blisters, erosions and scars. Based on the 2014 diagnosis and treatment guidelines, EB can be divided into four types: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome. DEB usually affects the skin and nails at birth, which can be divided into two subtypes, namely the dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). Furthermore, based on different clinical features, RDEB has been classified into severe Hallopeau-Siemens type (RDEB-HS) or the milder form called RDEB-nHS. Patients with RDEB-HS have systemic lesions and scars on hands and feet, leading to finger fusion and severe mucosal involvement, while those with RDEB-nHS may have local or systemic mild dermatological manifestations, mostly without finger fusion and without the involvement of the extradermal organs. Here, we report the case of a male patient with severe esophageal stricture due to recessive dystrophic EB. Currently, there is no effective treatment for EB complicated with severe esophageal stricture, although esophageal dilation and gastrostomy may be attempted.
- 23 March 2022
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 79, 10200
Open AccessCase Report: Recessive Dystrophic Epidermolysis Bullosa With Severe Esophageal Stenosis: A Case Report and Literature Review
Epidermolysis bullosa (EB) is a rare genetic disease that has no effective management or cure. Patients with EB may manifest with skin and mucous membrane fragility, blisters, erosions and scars. Based on the 2014 diagnosis and treatment guidelines, EB can be divided into four types: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome. DEB usually affects the skin and nails at birth, which can be divided into two subtypes, namely the dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). Furthermore, based on different clinical features, RDEB has been classified into severe Hallopeau-Siemens type (RDEB-HS) or the milder form called RDEB-nHS. Patients with RDEB-HS have systemic lesions and scars on hands and feet, leading to finger fusion and severe mucosal involvement, while those with RDEB-nHS may have local or systemic mild dermatological manifestations, mostly without finger fusion and without the involvement of the extradermal organs. Here, we report the case of a male patient with severe esophageal stricture due to recessive dystrophic EB. Currently, there is no effective treatment for EB complicated with severe esophageal stricture, although esophageal dilation and gastrostomy may be attempted.
- Open Access
- 8 March 2022
- Published by Springer Nature in Research Square
Multimolecular Characteristics and Role of BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1) in Human Tumors: A Pan-Cancer Analysis
Background The aberrant expression of BRIP1 was associated with several cancers, the panoramic picture of BRIP1 in human tumors is unclear. The purpose of this study is to explore the panoramic picture of expression of BRIP1 which was associated with several cancers. Methods Based on the data from TCGA, we utilized online databases to systematically analyze the multimolecular characteristics of BRIP1 in 33 human tumors. Results We observed prognosis-related differential BRIP1 expression between various carcinomas and the corresponding normal tissues. “Basal transcription factors”, “Homologous recombination”, “Nucleotide excision repair”, and DNA metabolism pathways may play a role in the functional mechanisms of BRIP1. Patients with uterine corpus endometrial carcinoma presented with the highest alteration frequency of BRIP1 (near 10%). Single nucleotide and copy number variation of BRIP1 were noticed in multiple cancer, and the expression of BRIP1 is significantly regulated by copy number variation in breast invasive carcinoma and lung squamous cell carcinoma. BRIP1 expression was negatively correlated to the methylation level in many human tumors, and the expression was associated with the activation of apoptosis, cell cycle, and DNA damage response, and inhibition of hormone ER and RNS/MARK signaling pathways. Moreover, a positive correlation was observed between BRIP1 expression and the immune infiltration level of cancer-associated fibroblasts and CD8 + T cells in lung adenocarcinoma. Conclusion Our pan-cancer analysis of BRIP1 provide valuable resource for understanding the characteristics of BRIP1 across human cancers.
- 8 March 2022
- Published by Springer Nature in Research Square
Open AccessMultimolecular Characteristics and Role of BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1) in Human Tumors: A Pan-Cancer Analysis
Background The aberrant expression of BRIP1 was associated with several cancers, the panoramic picture of BRIP1 in human tumors is unclear. The purpose of this study is to explore the panoramic picture of expression of BRIP1 which was associated with several cancers. Methods Based on the data from TCGA, we utilized online databases to systematically analyze the multimolecular characteristics of BRIP1 in 33 human tumors. Results We observed prognosis-related differential BRIP1 expression between various carcinomas and the corresponding normal tissues. “Basal transcription factors”, “Homologous recombination”, “Nucleotide excision repair”, and DNA metabolism pathways may play a role in the functional mechanisms of BRIP1. Patients with uterine corpus endometrial carcinoma presented with the highest alteration frequency of BRIP1 (near 10%). Single nucleotide and copy number variation of BRIP1 were noticed in multiple cancer, and the expression of BRIP1 is significantly regulated by copy number variation in breast invasive carcinoma and lung squamous cell carcinoma. BRIP1 expression was negatively correlated to the methylation level in many human tumors, and the expression was associated with the activation of apoptosis, cell cycle, and DNA damage response, and inhibition of hormone ER and RNS/MARK signaling pathways. Moreover, a positive correlation was observed between BRIP1 expression and the immune infiltration level of cancer-associated fibroblasts and CD8 + T cells in lung adenocarcinoma. Conclusion Our pan-cancer analysis of BRIP1 provide valuable resource for understanding the characteristics of BRIP1 across human cancers.
- 1 November 2020
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 31 (8) , 2304-2309
The Application of Three-Dimensional Technology Combined With Image Navigation in Nasal Skull Base Surgery
Three-dimensional (3D) technology including 3D reconstruction and 3D printing technology, has been widely used in clinical treatment, especially in surgical planning, and image navigation technology, which can make surgical procedures more accurate, now is also increasingly favored by surgeons. But the combination of those 2 technologies was rarely reported. Thus, this study will preliminarily investigate the feasibility and the effect of the combination of 2 technologies in endonasal skull base surgery. Eight patients were involved in this study (from October 2016 to July 2017 at The Affiliated Hospital of Qingdao University), 5 cases of nasal skull base tumors and 3 cases of foreign body perforation. All operations were done under the assistance of 3D technology and image guidance system. Surgical discussion with patient, preoperative planning and clinical teaching were investigated between 2D images and 3D models by voting. For all cases, 3D reconstruction model and 3D printed model were deemed to be more helpful than CT/MRI images in surgical discussion with the patient; surgical simulation on 3D model in preoperative planning was largely deemed to be helpful and very helpful; and in clinical teaching, 3D models combined with image guidance system were deemed to be more helpful in understanding the disease than using 2D images. Besides, all patients recovered well after surgery, no recurrence and complications were found in the follow-up. The combination of 3D technology and electromagnetic image guidance system could improve surgical efficiency and the quality of clinical teaching.
- 1 November 2020
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 31 (8) , 2304-2309
The Application of Three-Dimensional Technology Combined With Image Navigation in Nasal Skull Base Surgery
Three-dimensional (3D) technology including 3D reconstruction and 3D printing technology, has been widely used in clinical treatment, especially in surgical planning, and image navigation technology, which can make surgical procedures more accurate, now is also increasingly favored by surgeons. But the combination of those 2 technologies was rarely reported. Thus, this study will preliminarily investigate the feasibility and the effect of the combination of 2 technologies in endonasal skull base surgery. Eight patients were involved in this study (from October 2016 to July 2017 at The Affiliated Hospital of Qingdao University), 5 cases of nasal skull base tumors and 3 cases of foreign body perforation. All operations were done under the assistance of 3D technology and image guidance system. Surgical discussion with patient, preoperative planning and clinical teaching were investigated between 2D images and 3D models by voting. For all cases, 3D reconstruction model and 3D printed model were deemed to be more helpful than CT/MRI images in surgical discussion with the patient; surgical simulation on 3D model in preoperative planning was largely deemed to be helpful and very helpful; and in clinical teaching, 3D models combined with image guidance system were deemed to be more helpful in understanding the disease than using 2D images. Besides, all patients recovered well after surgery, no recurrence and complications were found in the follow-up. The combination of 3D technology and electromagnetic image guidance system could improve surgical efficiency and the quality of clinical teaching.
- 19 February 2020
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 68 (1) , 1-8
Desloratadine Ameliorates Olfactory Disorder and Suppresses AMPA Receptor GluA1 Expression in Allergic Rhinitis Rat
Allergic rhinitis (AR) is an IgE-mediated inflammation which causes olfactory dysfunction. Antihistamines have been widely used to treat AR while few studies have investigated the effect of antihistamines on improving the sense of smell. In addition, the underlying mechanisms are not well elucidated. We established the ovalbumin (OVA)-induced allergic rhinitis rat model and administrated desloratadine to AR rats. The AR symptoms, serum level of OVA-specific IgE and IL-17, and expression of IL-4, IL-5 and IL-13 in nasal mucosa were measured. The olfactory dysfunction was monitored by buried food test and the expression of GluR1 was measured. Desloratadine treatment alleviated AR symptoms, decreased serum level of OVA-specific IgE and IL-17 in AR rats. Desloratadine decreased IL-4, IL-5, and IL-13 expression in nasal mucosa of AR rats. Desloratadine ameliorated olfactory dysfunction in AR rats and decreased GluR1 expression in AR rats. Desloratadine treatment alleviated AR symptoms and ameliorated olfactory dysfunction in AR rats. The expression of AMPA receptor subunit GluR1 in olfactory bulb was associated with olfactory disorder.
- 19 February 2020
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 68 (1) , 1-8
Desloratadine Ameliorates Olfactory Disorder and Suppresses AMPA Receptor GluA1 Expression in Allergic Rhinitis Rat
Allergic rhinitis (AR) is an IgE-mediated inflammation which causes olfactory dysfunction. Antihistamines have been widely used to treat AR while few studies have investigated the effect of antihistamines on improving the sense of smell. In addition, the underlying mechanisms are not well elucidated. We established the ovalbumin (OVA)-induced allergic rhinitis rat model and administrated desloratadine to AR rats. The AR symptoms, serum level of OVA-specific IgE and IL-17, and expression of IL-4, IL-5 and IL-13 in nasal mucosa were measured. The olfactory dysfunction was monitored by buried food test and the expression of GluR1 was measured. Desloratadine treatment alleviated AR symptoms, decreased serum level of OVA-specific IgE and IL-17 in AR rats. Desloratadine decreased IL-4, IL-5, and IL-13 expression in nasal mucosa of AR rats. Desloratadine ameliorated olfactory dysfunction in AR rats and decreased GluR1 expression in AR rats. Desloratadine treatment alleviated AR symptoms and ameliorated olfactory dysfunction in AR rats. The expression of AMPA receptor subunit GluR1 in olfactory bulb was associated with olfactory disorder.
- 1 January 2020
- Vol. 34 (1) , 36-40
青岛地区变应性鼻炎患者变应原分布特点及发病相关危险因素
分析青岛地区变应性鼻炎(AR)患者的变应原分布情况及发病的相关危险因素。 将2018-08-2019-03期间就诊并诊断为AR的216例患者和49例健康志愿者, 共计271例(5~ 84岁)纳入流行病学调查研究, 进行吸入性变应原的皮肤点刺试验, 并对受试者进行过敏性疾病问卷调查和尘螨过敏自我检查问卷, 对结果进行分析统计。 ① 216例AR患者中阳性率排前6位的吸入性变应原依次为粉尘螨(55.0%)、屋尘螨(46.1%)、热带螨(21.8%)、狗毛(16.6%)、艾蒿(13.3%)、德国蟑螂(10.3%)。②吸入性变应原中, 屋尘螨和粉尘螨以(+++)为主, 艾蒿以(+++)和(++++)为主, 其他变应原均以(++)为主。③不同年龄段的吸入性变应原阳性率差异有统计学意义, 吸入性变应原阳性率在成年之后随着年龄增高而逐渐下降。④单因素、多因素逻辑回归分析均显示吸烟史、家族史、年龄 < 18岁及18~40岁等因素与AR的发生密切相关(P < 0.05)。⑤通过Spearson相关分析和loess回归分析发现, 随着尘螨自检评分的增高, 尘螨阳性率明显上升。 青岛地区AR患者最主要的吸入性变应原为尘螨、狗毛和艾蒿。吸入性变应原阳性率受年龄的影响并存在一定的规律。吸烟史、家族史、年龄等因素为AR发生的危险因素, 尘螨自检评分可以预测尘螨过敏的发生。
- 1 January 2020
- Vol. 34 (1) , 36-40
青岛地区变应性鼻炎患者变应原分布特点及发病相关危险因素
分析青岛地区变应性鼻炎(AR)患者的变应原分布情况及发病的相关危险因素。 将2018-08-2019-03期间就诊并诊断为AR的216例患者和49例健康志愿者, 共计271例(5~ 84岁)纳入流行病学调查研究, 进行吸入性变应原的皮肤点刺试验, 并对受试者进行过敏性疾病问卷调查和尘螨过敏自我检查问卷, 对结果进行分析统计。 ① 216例AR患者中阳性率排前6位的吸入性变应原依次为粉尘螨(55.0%)、屋尘螨(46.1%)、热带螨(21.8%)、狗毛(16.6%)、艾蒿(13.3%)、德国蟑螂(10.3%)。②吸入性变应原中, 屋尘螨和粉尘螨以(+++)为主, 艾蒿以(+++)和(++++)为主, 其他变应原均以(++)为主。③不同年龄段的吸入性变应原阳性率差异有统计学意义, 吸入性变应原阳性率在成年之后随着年龄增高而逐渐下降。④单因素、多因素逻辑回归分析均显示吸烟史、家族史、年龄 < 18岁及18~40岁等因素与AR的发生密切相关(P < 0.05)。⑤通过Spearson相关分析和loess回归分析发现, 随着尘螨自检评分的增高, 尘螨阳性率明显上升。 青岛地区AR患者最主要的吸入性变应原为尘螨、狗毛和艾蒿。吸入性变应原阳性率受年龄的影响并存在一定的规律。吸烟史、家族史、年龄等因素为AR发生的危险因素, 尘螨自检评分可以预测尘螨过敏的发生。
- Open Access
- 31 May 2019
- Published by Wiley in Cell Proliferation
- Vol. 52 (5) , e12638
Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway
Objectives: Terminally differentiated stratified squamous epithelial cells play an important role in barrier protection of the skin. The integrity of epidermal cells is maintained by tight regulation of proliferation and differentiation. The aim of this study was to investigate the role of epigenetic regulator H3K4me3 and its demethylase Jarid1b in the control of epithelial cell differentiation.Materials and methods: RT‐qPCR, Western blotting and IHC were used to detect mRNA and protein levels. We analysed cell proliferation by CCK8 assay and cell migration by wound healing assay. ChIP was used to measure H3K4me3 enrichment. A chamber graft model was established for epidermal development.Results: Our studies showed that H3K4me3 was decreased during epidermal differentiation. The H3K4me3 demethylase Jarid1b positively controlled epidermal cell differentiation in vitro and in vivo. Mechanistically, we found that Jarid1b substantially increased the expression of mesenchymal‐epithelial transition (MET)‐related genes, among which Ovol1 positively regulated differentiation gene expression. In addition, Ovol1 expression was repressed by PI3K‐AKT pathway inhibitors and overexpression (O/E) of the PI3K‐AKT pathway suppressor Ship1. Knockdown (KD) of Ship1 activated downstream PI3K‐AKT pathway and enhanced Ovol1 expression in HaCaT. Importantly, we found that Jarid1b negatively regulated Ship1 expression, but not that of Pten, by directly binding to its promoter to modulate H3K4me3 enrichment.Conclusion: Our results identify an essential role of Jarid1b in the regulation of the Ship1/AKT/Ovol1 pathway to promote epithelial cell differentiation.
- 31 May 2019
- Published by Wiley in Cell Proliferation
- Vol. 52 (5) , e12638
Open AccessJarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway
Objectives: Terminally differentiated stratified squamous epithelial cells play an important role in barrier protection of the skin. The integrity of epidermal cells is maintained by tight regulation of proliferation and differentiation. The aim of this study was to investigate the role of epigenetic regulator H3K4me3 and its demethylase Jarid1b in the control of epithelial cell differentiation.Materials and methods: RT‐qPCR, Western blotting and IHC were used to detect mRNA and protein levels. We analysed cell proliferation by CCK8 assay and cell migration by wound healing assay. ChIP was used to measure H3K4me3 enrichment. A chamber graft model was established for epidermal development.Results: Our studies showed that H3K4me3 was decreased during epidermal differentiation. The H3K4me3 demethylase Jarid1b positively controlled epidermal cell differentiation in vitro and in vivo. Mechanistically, we found that Jarid1b substantially increased the expression of mesenchymal‐epithelial transition (MET)‐related genes, among which Ovol1 positively regulated differentiation gene expression. In addition, Ovol1 expression was repressed by PI3K‐AKT pathway inhibitors and overexpression (O/E) of the PI3K‐AKT pathway suppressor Ship1. Knockdown (KD) of Ship1 activated downstream PI3K‐AKT pathway and enhanced Ovol1 expression in HaCaT. Importantly, we found that Jarid1b negatively regulated Ship1 expression, but not that of Pten, by directly binding to its promoter to modulate H3K4me3 enrichment.Conclusion: Our results identify an essential role of Jarid1b in the regulation of the Ship1/AKT/Ovol1 pathway to promote epithelial cell differentiation.
- 28 November 2018
- Published by Impact Journals, LLC in Aging
- Vol. 10 (11) , 3474-3485
TGF-β induces corneal endothelial senescence via increase of mitochondrial reactive oxygen species in chronic corneal allograft failure
The corneal endothelium (CE) dysfunction impairs optical transparency and leads to corneal allograft failure. Morphologically, CE cells are characterized by premature senescence at the late stage of corneal graft. However, the detailed molecular mechanisms are largely unknown. Here we found that transforming growth factor-β (TGF-β) is elevated in the CE of late graft failure. In addition, senescence-associated gene p21 and p16 are increased as well, which is consistent with their elevation upon TGF-β treatment in human corneal endothelial cell B4G12. Furthermore, TGF-β treatment leads to high positive ratio of SA-β-gal, indicating B4G12 cells undergo cellular senescence. Mechanistically, we demonstrated that TGF-β could induce mitochondrial ROS (mtROS) production and mtROS scavenger could rescue CE cell senescence upon TGF-β treatment. Our study provides new evidence that elevated TGF-β plays a crucial role in the CE cell senescence and loss in chronic corneal graft failure, which could be potential targets for clinical treatment.
- 28 November 2018
- Published by Impact Journals, LLC in Aging
- Vol. 10 (11) , 3474-3485
TGF-β induces corneal endothelial senescence via increase of mitochondrial reactive oxygen species in chronic corneal allograft failure
The corneal endothelium (CE) dysfunction impairs optical transparency and leads to corneal allograft failure. Morphologically, CE cells are characterized by premature senescence at the late stage of corneal graft. However, the detailed molecular mechanisms are largely unknown. Here we found that transforming growth factor-β (TGF-β) is elevated in the CE of late graft failure. In addition, senescence-associated gene p21 and p16 are increased as well, which is consistent with their elevation upon TGF-β treatment in human corneal endothelial cell B4G12. Furthermore, TGF-β treatment leads to high positive ratio of SA-β-gal, indicating B4G12 cells undergo cellular senescence. Mechanistically, we demonstrated that TGF-β could induce mitochondrial ROS (mtROS) production and mtROS scavenger could rescue CE cell senescence upon TGF-β treatment. Our study provides new evidence that elevated TGF-β plays a crucial role in the CE cell senescence and loss in chronic corneal graft failure, which could be potential targets for clinical treatment.